SCHEMBL1821097

SCHEMBL1821097

O[C@H]1CCC[C@@H](O)CCC1

nearest known ligand 0.82

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.82
ESR2 Q92731 1/20 0.40
GPR119 Q8TDV5 1/20 0.33
EPHX2 P34913 1/20 0.33
SHBG P04278 1/20 0.32
CA1 P00915 2/20 0.32
CA2 P00918 2/20 0.32
NOS2 P35228 1/20 0.32
CA4 P22748 1/20 0.32
CA12 O43570 1/20 0.31
CA9 Q16790 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9225512 1.00 TSHR (0.82) TSHRESR2GPR119EPHX2SHBG
SCHEMBL11691617 1.00 TSHR (0.82) TSHRESR2GPR119EPHX2SHBG
SCHEMBL328907 1.00 TSHR (0.82) TSHRESR2GPR119EPHX2SHBG
SCHEMBL15832112 0.95 TSHR (0.91) TSHRESR2GPR119EPHX2SHBG
SCHEMBL3098062 0.95
SCHEMBL13888940 0.95
SCHEMBL15832048 0.95 TSHR (0.91) TSHRESR2GPR119EPHX2SHBG
SCHEMBL3098068 0.95
SCHEMBL11324930 0.95 TSHR (0.91) TSHRESR2GPR119EPHX2SHBG
SCHEMBL1115888 0.95

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12098244-B2 Process for synthesising semi-aromatic polyethers ROQUETTE FRERES (FR) 2024-09-24 US claimed
EP-2374853-A1 Cyanate ester-based pressure sensitive adhesive CORNERSTONE RESEARCH GROUP, INC. (US) 2011-10-12 EP claimed
US-20100137554-A1 SHAPE MEMORY CYANATE ESTER COPOLYMERS CORNERSTONE RESEARCH GROUP, INC. 2010-06-03 US claimed
US-5169438-A Storage stability, quick-drying E. I. DU PONT DE NEMOURS AND COMPANY (US) 1992-12-08 US claimed
JP-5179184-A None JP disclosed
US-12098244-B2 Process for synthesising semi-aromatic polyethers ROQUETTE FRERES (FR) 2024-09-24 US disclosed
US-12048710-B2 Compositions and methods for modification of biomolecules THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-07-30 US disclosed
US-11672791-B2 Tyrosine kinase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2023-06-13 US disclosed
US-11672791-B2 Tyrosine kinase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2023-06-13 US disclosed
US-20230012676-A1 TYROSINE KINASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2023-01-19 US disclosed
US-20220202837-A1 COMPOSITIONS AND METHODS FOR MODIFICATION OF BIOMOLECULES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2022-06-30 US disclosed
US-20220177648-A1 PROCESS FOR SYNTHESISING SEMI-AROMATIC POLYETHERS ROQUETTE FRERES (FR) 2022-06-09 US disclosed
WO-1990009383-A1 HERBICIDAL OXABICYCLONONANE ETHERS E.I. DU PONT DE NEMOURS AND COMPANY (US) 1990-08-23 WO disclosed
EP-0383469-A1 Herbicidal oxabicyclononane ethers E.I. DU PONT DE NEMOURS AND COMPANY (US) 1990-08-22 EP disclosed
US-4546136-A Organotin-containing composition for the stabilization of polymers of vinyl chloride AKZO N.V. (NL) 1985-10-08 US disclosed
EP-0129264-A2 Organotin-containing composition for the stabilization of polymers or copolymers of vinyl chloride AKZO N.V. (NL) 1984-12-27 EP disclosed
EP-0025288-B1 DERIVATIVES OF MONIC ACID, PROCESSES FOR THEIR PREPARATION, COMPOSITIONS CONTAINING THEM AND THEIR PREPARATION BEECHAM GROUP PLC (GB) 1983-04-06 EP disclosed
US-4342849-A OLEFIN POLYMERS HAVING HYDROXY TERMINAL GROUPS THE UNIVERSITY OF AKRON (US) 1982-08-03 US disclosed
US-4316973-A Novel telechelic polymers and processes for the preparation thereof THE UNIVERSITY OF AKRON (US) 1982-02-23 US disclosed
EP-0025288-A1 Derivatives of monic acid, processes for their preparation, compositions containing them and their preparation BEECHAM GROUP PLC (GB) 1981-03-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12048710-B2 Compositions and methods for modification of biomolecules PTMS, QPCT, ANPEP TSHR 1564/4885ESR2 4315/4885GPR119 1711/4885
US-20220202837-A1 COMPOSITIONS AND METHODS FOR MODIFICATION OF BIOMOLECULES PTMS, QPCT, ANPEP TSHR 1564/4885ESR2 4315/4885GPR119 1711/4885
US-20230012676-A1 TYROSINE KINASE INHIBITORS TYRO3, AXL, RET TSHR 295/4885ESR2 1786/4885GPR119 80/4885
US-11672791-B2 Tyrosine kinase inhibitors TYRO3, AXL, RET TSHR 295/4885ESR2 1786/4885GPR119 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.